While I would agree that the PP's at current valuation are favourable to the current OTC price it still is seems to me a sizeable management failure that the price for arguably equal or superior IP plus a proportionate share of the RVX royalty preference shares is not worth something closer to the price of Constellation. I think management needs to work on selling a position to one of their BP trial partners at a fair price and then using that as a bench mark for PP's. Not the same as, but similar to when quite awhile back Trillium sold 10 million shares to Pfizer at premium to market. Is what it is right now though. 

I would still rather see ZCC sold at a fair price, that would be be my choice for getting $$ into investors hands. I would think the IP plus the royalty preferred would make a nice package.